CTOs on the Move

Trevi Therapeutics

www.trevitherapeutics.com

 
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Trevi Therapeutics raised $50.5M on 07/20/2017
Trevi Therapeutics raised $55M on 04/07/2022

Similar Companies

FDC Vitamins

FDC Vitamins is a Hialeah, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Standard Bariatrics

Cincinnati-based surgical procedure company focused on innovative development, commercialization of medical devices for treatment of obesity, gastrectomy.

Basic Research

Basic Research, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Regulatory Applications and Strategy Consulting

Regulatory Applications and Strategy Consulting is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OptioRx